Background and aims: Infliximab is currently the only biologic approved for treatment of adults with moderate to severe, active ulcerative colitis (UC) unresponsive to conventional therapies. It rapidly controls symptoms, induces and sustains steroid-free remission, stimulates mucosal healing, and reduces serious complications. Although infliximab tends to be reserved for
Introduction
Ulcerative colitis (UC) is a chronic inflammatory disease of the colon with a varying course that can range from dormant to refractory. Solberg et al. posit 4 patterns: initial high activity to remission or mild severity; initial low activity to increased severity; continuous symptoms; and intermittent symptoms. 1 UC may become milder with increasing age, but relapse is still common in patients with mild-to-moderate disease. 1 UC is conventionally treated with symptom-focused step-up therapy comprising aminosalicylates, corticosteroids, and immunomodulators (e.g., 6-mercaptopurine or azathioprine [AZA]). While a 1994 assessment showed that with this approach UC remained active in up to 50% of patients after a few years, and one-fifth of these patients required colectomy within 10 years, 2 a more recent assessment is less gloomy: only one-tenth of conventionally treated patients required colectomy within 10 years. 1 The course of UC in these patients is unclear, but corticosteroid use has been associated with poor prognosis in up to 50% of patients. 3 Furthermore, although AZA is regularly used to treat patients with UC not responding to aminosalicylates and corticosteroids, evidence supporting its use is limited. One meta-analysis suggested that the probability of treatment success with AZA is similar to, or at best marginally more beneficial than, aminosalicylates or placebo.
It is now recognized that treatment goals must go beyond controlling symptoms, to influencing the underlying cause of UC via fast, sustained control of inflammation. UC treatment should aim to rapidly induce steroid-free remission, achieve complete mucosal healing (an objective indicator of inflammation control and bowel normalisation), avoid serious complications (e.g., hospitalisations and surgeries), minimize side effects, and improve patient quality of life (QoL). 5 Achievement of these challenging treatment goals is possible in more patients since the introduction of biologic therapies.
Currently, infliximab is the only biologic therapy approved for treatment of UC. It was approved in 2006 by the European Commission for the treatment of moderate to severe, active UC in patients with an inadequate response to conventional therapy, including corticosteroids and 6-MP or AZA, or who are intolerant or have medical contraindications to such therapies. 6 In addition, the European Crohn's and Colitis Organisation (ECCO) UC management guidelines recommend infliximab in steroid-refractory and thiopurine-refractory UC. 7 Infliximab tends to be used as a third-line therapy in patients with moderate to severe UC or as a rescue therapy. However, experts have proposed that earlier use during less severe disease states (i.e., moderate UC) could benefit many patients. 5 Furthermore, infliximab can potentially attain the new treatment goals beyond symptom control in these patients. [8] [9] [10] Interestingly, combination therapy with infliximab and AZA may be the new best approach, according to results from a doubleblind, randomized, controlled trial (RCT) presented at the ECCO conference, 11 but not yet published in full. The objective of the present survey was to assess current expert practices and establish pragmatic principles for candidate selection and timing of infliximab therapy. It is hoped that the results of this cooperative effort will assist clinical practice.
Materials and methods

Survey participants
A steering committee comprising 3 gastroenterologists (WR, GvA, and JP) with extensive experience using biologic therapy to treat UC, both in clinical trials and the clinical setting, helmed the Delphi process. Committee members developed topics for the survey and helped with design and methodology (Table 1) , but did not participate in the survey. When complete, the survey was reviewed by the steering committee and then independently tested to ensure that the questions were understandable, with no ambiguities.
Twelve gastroenterologists from Europe, Canada, and Australia agreed to form an expert panel and to participate in the survey under the supervision of the steering group. The members of the expert panel were selected based on their substantial level of expertise in using biologic therapy in the treatment of UC in both clinical practice and clinical studies (Table 1) .
Delphi methodology
The Delphi methodology, developed by Linstone and Turoff, provides an evidence-based method for structured group communication that allows a group of individuals to effectively explore and solve complex problems. 12 A major strength of this approach is that it can be used to look at a specific problem/argument from all angles, determine the pros and cons of different approaches to the problem, and help clarify the impact and acceptability of specific ideas and opinions. 12, 13 The Delphi methodology modifies individual viewpoints and leads to a merging of opinion within a group.
The Delphi methodology has been modified to allow establishment of a consensus. Known as the "collaborative Delphi," this modification uses a combination of surveys and meetings. The approach involves a steering group that identifies the issues surrounding a complex problem, and a survey questionnaire to which an expert panel anonymously responds. By undergoing repeated rounds of the survey and subsequent analysis/modification of the questions, it is possible to reach a group consensus.
In this study, consensus was reached using the collaborative Delphi method, which was executed in 2 rounds of an anonymous survey (rounds 1 and 2) followed by a meeting (round 3). During the meeting, the anonymity of the expert panel members was relinquished. Individual survey responses were not disclosed, however, to maintain objectivity. Consensus was reached on many topics at the end of the meeting, and additional questions were developed which were then sent to the expert panel to be answered anonymously (round 4). Questions were formulated to measure areas of agreement, relevance, importance, and likelihood of action. A Likert scale of 1 to 9 was used, where a score of 1, 2, 3 or 4 indicated degrees of disagreement with the statement or question, and a score of 6, 7, 8 or 9 indicated increasing degrees of agreement. A score of 5 was considered neutral. The expert panel completed the internet-based questionnaire during rounds 1 and 2 of the Delphi process. A numerical identification system ensured that the participants remained anonymous.
Data analysis
After completion of round 1, the responses were collected and analyzed as a group. Median scores were calculated to obtain an accurate measure of main tendencies and discount any extreme views. During round 2, these median scores were made known to the expert panel. After this round of the Delphi process and before the round 3 meeting occurred, the variability of the responses was calculated using the interquartile range (IQR; a measure of the distance between the 75th and 25th percentiles that reflects the middle 50% of responses). IQR gives a stable measure of the response range that is not swayed by outliers or extreme responses.
The results of the survey were presented to the expert panel by the steering committee during a meeting (round 3). Key issues surrounding the use of biologic therapy in UC were discussed to establish importance, relevance to patient treatment, and likelihood of specific actions (e.g., use of cyclosporine over infliximab). To further clarify the degree of agreement with a question or statement, the median Likert scoring scale was adjusted. Statements or questions were re-categorised as "highly irrelevant, strongly disagree, or highly unlikely" (median score 1-3); "somewhat relevant or irrelevant, somewhat agree or disagree, or somewhat likely or unlikely" (median score 4-6); or "highly relevant, strongly agree, or highly likely" (median score 7-9). Positive consensus was defined as the median ≥ 7 plus the lower quartile ≥ 7 (negative consensus, median ≤ 3 and upper quartile ≤ 3). Scores can be illustrated with "boxplots" (Fig. 1) . Each consensus was based on expert opinion and clinical experience.
Results
Delphi participants based their responses on their familiarity with and knowledge about infliximab, because at the time of this survey it was the only biologic approved for the treatment of UC. safety, the panel reached consensus that the following are important when considering biologic therapy in patients with UC:
Factors influencing the decision to use biologic therapy
Factors influencing the decision to use infliximab 3.2.1. Treatment goals
The panel recognized the importance of going beyond symptom control to achieve additional treatment objectives (Table 2 were determined to be highly relevant factors in the decision to select infliximab for UC patients.
Patient selection
Panelists agreed that they would recommend infliximab to candidates ≥ 16 years old and up to 70 years old (median 8 ). However, no consensus was reached on recommending infliximab to patients older than 70 (median 6 [IQR 5.0-6.5]), and the most relevant factor to this decision in this age group was safety (median 8 ). Malignancy (median 6 [IQR 4.5-7.5]) and surgical risks (median 7 [IQR 5.5-7.5]) were deemed by some to be relevant to the decision. Experts also were asked about the likelihood they would recommend infliximab to a female candidate with established UC who was pregnant or wished to become pregnant. Consensus was lacking regarding existing pregnancy (median 7 ), although the majority were highly likely to recommend infliximab to those planning pregnancy (median 7 ). Several other patient-and diseasespecific factors also were considered highly influential in the decision to use infliximab ( 
Disease status
Of assessment measures, results of the Physician Global Assessment were considered highly relevant (median 8 ) in the decision to treat UC with infliximab. No consensus could be reached on the relevance of multiple other clinical factors, including endoscopic involvement, histology grade, laboratory results (e.g., elevated CRP and ESR), and previous medications. The panel agreed that patients with persistently active UC and steroid dependence or resistance must be identified correctly to ensure appropriate 
Factors related to timing of infliximab therapy
Some of the expert panel agreed that initiating infliximab when disease is not yet severe, earlier in the course of UC, increases the likelihood of achieving treatment goals, i.e., symptom relief, reduced flares, mucosal healing, fewer complications (hospitalisation and surgeries), and improved QoL, but there was no consensus. Consensus was reached only on the statement that using infliximab earlier in the course of disease increases the likelihood of reducing patient dependence on steroids (median 8 [IQR 7-8]).
Issues regarding surgery for ulcerative colitis
Most of the panel agreed that patient fear of the surgical procedure and patient age N 70 were highly relevant in the decision to use infliximab. Consensus was reached that patient fears about the consequences of surgery (median 7 [IQR 7-8]) and possible surgical complications (median 7 [IQR 7.0-7.5]), and patient desire to avoid surgery (median 7 [IQR 7-8]) were highly relevant to the decision. Consensus Table 4 Definitions from ECCO guidelines and definitions produced by the expert panel.
Definitions from ECCO guidelines 
Infliximab as an alternative to surgery
The expert panel stated that they routinely consult with surgeons prior to making treatment decisions in patients suitable for elective colectomy or infliximab therapy.
Consensus was reached that infliximab can be used as an alternative to surgery in many patients with acute, severe UC at imminent risk of colectomy (Fig. 2) . The expert panel agreed that many patients with moderate to severe, persistently active UC considered at risk of colectomy, or those with severe UC failing intravenous (IV) steroids are candidates for infliximab. The expert panel would use infliximab rather than cyclosporin in patients with severe active or chronic acute UC as an alternative to surgery, because infliximab was considered safer and easier to administer. There was consensus that treating acute UC patients with infliximab prolongs the time to colectomy (median 8 
Discussion
The results of this Delphi survey underscore the potential of biologic therapy to change the disease course in UC. The expert panelists identified speed of clinical improvement, ability to achieve mucosal healing, better QoL, and avoidance of colectomy as critical factors in the decision to recommend biologic therapy to their patients. A variety of other factors also were deemed highly relevant, including previous treatment failures and presence of extraintestinal manifestations. Although the survey included questions about cost and reimbursement, consensus could not be reached due to regional reimbursement rules. Consensus was achieved in many other areas, however (Table 5) .
Accurate identification of candidates for biologic therapy is essential-the panel achieved consensus on this point. Therefore, the definitions of "persistently active," "steroid dependent," and "steroid resistant" UC and of "remission" are important to ensure appropriate treatment. There was accord among panelists that the ECCO guidelines provide useful definitions, and the panelists expanded them with specific criteria.
The panelists were in consensus that their decisions to use infliximab were based on clinical trial data (median 8 ) showing significant clinical response within 8 weeks, ability to achieve clinical remission and discontinue steroids, and stimulation of mucosal healing, as well as on Mucosal healing can be sustained with infliximab over time.
Persistence of mucosal lesions is a factor in my decision to use in fliximab, once clinical parameters warrant biologic therapy.
How relevant is achievement of mucosal healing by patients receiving infliximab in your decision to use infliximab? Infliximab reduces the likelihood of colectomy in patients with persistent, active UC.
Achieving mucosal healing in UC reduces the risk of colectomy.
Patients with persistent, moderate to severe, active UC who are at risk of colectomy are candidates for infliximab. Figure 2 The decision to use biologic therapy/infliximab ⁎ and issues related to surgery for UC (survey topics 2 and 4). Areas of consensus included the benefits of biologic therapy to mucosal healing and the potential to prolong the time to, or avoid, colectomy. *At the time of this survey, infliximab was the only biologic approved for the treatment of UC.
long-term safety data (median 7.5 [IQR 7-8]) from inflammatory bowel disease (IBD) cohorts and registries. (For example, see 8, 9, 14, 15 .) There was positive consensus that in some patients, infliximab has the potential to: improve symptoms, reduce flares, stimulate mucosal healing, reduce hospitalizations and surgeries, reduce dependence on steroids, improve QoL, restore productivity, and achieve steroid-free clinical remission.
Panelists strongly agreed that restoring QoL is an important treatment goal. The symptoms of active UC (e.g. nocturnal diarrhea, urgency, incontinence, tenesmus and pain) can have a significantly negative effect. The impact must be reduced so that patients can perform at work and enjoy leisure activities, both of which encourage feelings of social acceptability. Also, patients' stress/anxiety about disease symptoms and long-term effects, and any fears regarding surgery must be addressed. Importantly, perceptions of QoL vary, so interpretations of improvement should be assessed on a patient-by-patient basis. There was strong consensus among panelists that the goal of restoring QoL was highly relevant in the decision to recommend infliximab.
Panelists strongly agreed that using infliximab earlier in the course of disease may improve the likelihood of achieving treatment goals. Currently, infliximab tends to be used in patients with more severe disease. Although there is strong evidence in Crohn's disease (CD) showing benefits of initiating infliximab early, 16 the data in UC is scant. Some experts recommend considering use of infliximab in patients with moderately severe UC who are steroid-dependent or steroidrefractory. 5 Our expert panel reached positive consensus in agreeing with this recommendation (median 8 [IQRs 7-8 and 8-9, respectively]). Interestingly, data for use of infliximab in patients with moderate disease is building. In a cohort of 115 patients receiving infliximab, those with moderately severe compared with severe UC had a higher rate of clinical response (70% vs. 41%, P = 0.004) and clinical remission (41% vs. 17%, P = 0.015). 17 A posthoc analysis of data from the Active Controlled Ulcerative Colitis Trial (ACT) 1 and 2 8 showed that infliximab patients who had mucosal healing at week 8 (Mayo endoscopic subscore classification 0 -normal or 1 -mild) were less likely to progress to colectomy at week 54 (P = 0.0004). 18 Note that 63.8% of these patients (309/484) had moderate disease at baseline. 19 UC SUCCESS, a 16-week trial in biologic-naïve patients with moderately severe UC, is now complete. Patients were failing corticosteroids and either naïve to AZA or had stopped AZA ≥3 months before entry. Combination therapy with infliximab and AZA was found to be superior to both AZA (P b 0.05) and IFX (nominal P b 0.05) monotherapy in inducing steroid-free remission in patients with moderately severe UC.
11 Also, patients treated with an IFX-based strategy were more likely to achieve response and mucosal healing than those treated with AZA monotherapy. A full report of this trial has not yet been published, but the data have been orally presented at ECCO 2011. 11 The results must be extended and investigated further.
Some patients have a more progressive form of UC that is associated with poor outcomes (e.g., increased hospitalizations and colectomy and mortality rates). Predictive factors of poor prognosis in UC have been identified. A subanalysis of ACT 1 and 2 revealed that steroid dependency, high (≥ 2 mg/dL) baseline C-reactive protein (CRP), high disease severity (Mayo 10-12), and moderate to severe, active UC of short disease duration (≤ 3 years) were significantly associated with increased risk of colectomy. 10 In a retrospective single-center analysis, independent predictors of colectomy included absence of short-term clinical response, baseline CRP ≥ 5 mg/dl, and previous intravenous treatment with cyclosporine and/or corticosteroids. 9 A multicenter study had similar results, with the addition of a diagnosis of acute severe colitis. 20 In routine clinical practice, physicians have to decide when to initiate infliximab therapy and for which patients. Currently, there are limited published data from large RCTs on selecting patients with these identifying factors for treatment with infliximab before rapid progression. Patients with moderate to severe, active UC may require surgery for refractoriness to conventional treatments or for complications of their disease. The ACT trials showed that infliximab significantly reduces the risk of UC-related hospitalisations and surgeries. 10 Importantly, infliximab is an effective rescue therapy in patients with severe or moderately severe UC not responding to conventional therapy. 21, 22 Cyclosporin also is effective initially for rescue therapy, but many patients will require colectomy in the long term. 23 Patients with 6-MP/AZA failure who subsequently receive cyclosporin are especially at risk of colectomy. 23 Moreover, the necessity of frequent monitoring and the toxicity risk associated with cyclosporin tend to make infliximab more appealing to gastroenterologists. An RCT comparing infliximab and cyclosporine has not been published, but preliminary data suggest equal efficacy in 111 patients failing IV steroids. 24 In a recent retrospective survey of 86 patients with steroid-refractory UC or indeterminate colitis, 65 had failed to respond to cyclosporine and were treated with infliximab as the second-line rescue therapy (CYS-IFX), and 21 had failed to respond to infliximab and were treated with cyclosporine second-line (IFX-CYS). 25 Median follow-up was 22.6 ± 7.0 months. At month 3, 25% of patients (16/65) in the CYS-IFX subgroup and 14% of patients (3/21) in the IFX-CYS subgroup were in remission without steroids. (Three additional were in remission but with steroids.) Among the 65 patients treated with CYS-IFX, 35 (54%) were operated. Among the 21 patients treated with IFX-CYS, 14 (67%) were operated. The colectomy rate was similar whatever agent was used as the first salvage therapy. No difference in Kaplan-Meier colectomy-free survival curves was observed between the groups. In this study, a significant number of patients avoided colectomy by switching these agents for secondline therapy. 25 IFX-CYS rescue therapy is administered to patients with severely acute UC in hospital only.
This discussion would not be complete without addressing areas of non-consensus in our Delphi process. These areas, which arose due to lack of data, included prescribing infliximab to pregnant patients or to those N 70 years old. Age N70 was considered highly relevant in the decision to use infliximab if the other option was surgery. A recent Austrian (non-Delphi) consensus on safety issues related to use of infliximab in IBD noted, as does infliximab product labeling, 6 that no studies have focused on the safety of infliximab in the elderly. 26 Sparse data constrained these experts, who issued 1 statement pertaining to this demographic: "Close monitoring for infectious complications is mandatory in IBD patients with higher age."
A subsequent subanalysis demonstrated harmful effects in the elderly. 27 Comparison between a prospectively recruited study group of 95 patients N 65 years old treated with infliximab or adalimumab and retrospective matched controls (190 patients ≤65 years old treated with both biologics plus 190 patients N65 years old treated with other drugs) showed that those N 65 years old and treated with TNF inhibitors (TNFi) had a high rate of infections and mortality compared with younger patients, or same-age patients who did not receive TNFi. However, these results must be viewed with caution due to several study limitations (e.g., retrospective controls, uncertainty about whether disease severity was greater in biologically treated control patients, innate higher risk of infection in elderly due to comorbidities, mortality already higher in elderly with IBD). 27 Therefore the message reiterates product labeling in recommending that particular attention be paid to treatment of the elderly.
Similarly, our Austrian colleagues could make no recommendation to continue or initiate infliximab during pregnancy. 26 The product label recommends against it. 6 However, ECCO has rated infliximab as "probably safe" during pregnancy and lactation, with the following official statements 28 :
• Use of 5-ASA derivatives, corticosteroids and biologicals is not significantly associated with malformations or adverse outcomes in pregnant IBD patients and their offspring.
• All anti-TNFs are likely to be excreted in the breast milk in very small amounts. However, no adverse effects have been reported in the small number of infants breastfed by mothers on this therapy.
• Infliximab is of low risk in pregnancy, both for the early and late outcomes, and does not seem to be a teratogenic.
The World Congress of Gastroenterology has taken a nearly identical position. 29 However available data are mostly observational only. [30] [31] [32] [33] Moreover, outcomes of 130 pregnancies in the U.K. British Society for Rheumatology Biologics Register (BSRBR) led researchers to conclude that no firm conclusions can be drawn about use of TNFi in pregnancy, and such treatment during conception may even be associated with increased risk of spontaneous abortion. 34 Since our Delphi was conducted, conflicting evidence has accumulated for both a lack of infliximab-associated adverse pregnancy outcomes 35, 36 and cause for concern 32,37 -sometimes in the same article. 33 There is general agreement, however, that infliximab should be stopped during the last trimester of pregnancy.
The relevance of disease status in choosing to use infliximab also was an area of non-consensus in our Delphi. This result is perhaps unsurprising, since with multiple disease distribution patterns, activity levels, and possible courses, UC presents a minimum of 48 different scenarios for consideration-not including critical factors such as age, concomitant illnesses, and previous medications and surgeries. 38 Additionally, while the ECCO guidelines 7 provide useful definitions of disease states, they do not specify the significance of multiple clinical factors. To our knowledge, this has not yet been done in UC. Furthermore, although efforts in CD to identify patients at risk and predict outcomes of various treatments have provided valuable information, comparatively little is known in UC. 38, 39 A thorough examination of these factors is beyond the scope of this article. But clearly, more research is needed upon which expert panels such as ours may base their opinions and thereby reach consensus.
